

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT7044545

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
MIHAEL H. POLYMEROPOULOS	09/06/2018
SANDRA SMIESZEK	09/05/2018
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	VANDA PHARMACEUTICALS INC.
<b>Street Address:</b>	2200 PENNSYLVANIA AVENUE NW
<b>Internal Address:</b>	SUITE 300-E
<b>City:</b>	WASHINGTON
<b>State/Country:</b>	D.C.
<b>Postal Code:</b>	20037
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	17536306
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(518)449-0047
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	5184490044
<b>Email:</b>	ptocommunications@hoffmanwarnick.com, mpaul@hoffmanwarnick.com
<b>Correspondent Name:</b>	HOFFMAN WARNICK LLC
<b>Address Line 1:</b>	540 BROADWAY
<b>Address Line 2:</b>	4TH FLOOR
<b>Address Line 4:</b>	ALBANY, NEW YORK 12207
<b>ATTORNEY DOCKET NUMBER:</b>	VAND-0182-US-CON
<b>NAME OF SUBMITTER:</b>	JAYME M. TORELLI
<b>SIGNATURE:</b>	/Jayme M. Torelli/
<b>DATE SIGNED:</b>	11/29/2021
<b>Total Attachments: 4</b>	
source=VAND-0182-US_SignedAssignment_16AUG2019#page1.tif	
source=VAND-0182-US_SignedAssignment_16AUG2019#page2.tif	

source=VAND-0182-US\_SignedAssignment\_16AUG2019#page3.tif

source=VAND-0182-US\_SignedAssignment\_16AUG2019#page4.tif

ASSIGNMENT

Whereas, we, below named and undersigned inventors, have made certain inventions, improvements, and discoveries (herein referred to as the "Invention") in:

Title of the Invention: **GENETIC MARKERS FOR ENHANCING EFFICACY OF  
ANTIPSYCHOTIC TREATMENT WITH ILOPERIDONE**

and further identified by the Docket Number provided above in the header of this Assignment, for which an application for a United States Patent was executed concurrently herewith or was filed having:

US Provisional Application No.: 62/725,016, filed August 30, 2018.


Whereas, Vanda Pharmaceuticals Inc., a corporation of Delaware, having a place of business at 2200 Pennsylvania Avenue NW, Suite 300-E, Washington, D.C. 20037 (herein referred to as "ASSIGNEE"), desires to acquire, and we desire to grant to ASSIGNEE, our entire worldwide right, title, and interest in and to the Invention and in and to any and all patent applications and patents directed thereto;

Now, therefore, for good and valuable consideration, the receipt and sufficiency thereof being hereby acknowledged, we ("ASSIGNOR") hereby sell or have sold, assign or have assigned, and otherwise transfer or have transferred to Vanda Pharmaceuticals Inc. (the "ASSIGNEE"), its successors, legal representatives, and assigns, my entire worldwide right, title, and interest in and to the Invention, the above-identified United States patent application, and any and all other patent applications and patents for the Invention which may be applied for or granted therefor in the United States and in all foreign countries and jurisdictions, including all divisions, continuations, reissues, reexaminations, renewals, extensions, counterparts, substitutes, and extensions thereof, and all rights of priority resulting from the filing of such applications and granting of such patents. In addition, we hereby authorize and request the Director of the United States Patent and Trademark Office to issue any United States Patent, and foreign patent authorities to issue any foreign patent, granted for the Invention, to ASSIGNEE, its successors, legal representatives, and assigns, my entire worldwide right, title, and interest in and to the same to be held and enjoyed by ASSIGNEE, its successors, legal representatives, and assigns to the full end of the terms for which any and all such patents may be granted, as fully and entirely as would have been held and enjoyed by us had this Assignment not been made; and we agree to execute any and all documents and instruments and perform all lawful acts reasonably related to recording this Assignment or perfecting title to the Invention and all related patents and applications, in ASSIGNEE, its successors, legal representatives, and assigns, whenever requested by ASSIGNEE, its successors, legal representatives, or assigns.

We acknowledge our prior and ongoing obligations to sell, assign, and transfer our rights under this Assignment to ASSIGNEE, and are unaware of any reason why we may not have the full and unencumbered right to sell, assign, and transfer our rights hereby sold, assigned, and transferred, and have not executed, and will not execute, any document or instrument in conflict herewith. We also hereby grant ASSIGNEE, its successors, legal representatives, and assigns, the right to insert in this Assignment any further identification (including, but not limited to, patent Application Number) which may be necessary or desirable for recordation of this Assignment. This Assignment is governed by the substantive laws of the State of New York, and any disputes will be resolved in a New York state court or federal court sited in New York.

(1) Name of Inventor: Mihael H. Polymeropoulos

Signature: \_\_\_\_\_



Date: \_\_\_\_\_

9/6/2018

(2) Name of Inventor: Sandra Smieszek

Signature: \_\_\_\_\_

Date: \_\_\_\_\_

**ASSIGNMENT**

Whereas, we, below named and undersigned inventors, have made certain inventions, improvements, and discoveries (herein referred to as the "Invention") in:

Title of the Invention: **GENETIC MARKERS FOR ENHANCING EFFICACY OF  
ANTIPSYCHOTIC TREATMENT WITH ILOPERIDONE**

and further identified by the Docket Number provided above in the header of this Assignment, for which an application for a United States Patent was executed concurrently herewith or was filed having:

US Provisional Application No.: 62/725,016, filed August 30, 2018.

Whereas, Vanda Pharmaceuticals Inc., a corporation of Delaware, having a place of business at 2200 Pennsylvania Avenue NW, Suite 300-E, Washington, D.C. 20037 (herein referred to as "ASSIGNEE"), desires to acquire, and we desire to grant to ASSIGNEE, our entire worldwide right, title, and interest in and to the Invention and in and to any and all patent applications and patents directed thereto;

Now, therefore, for good and valuable consideration, the receipt and sufficiency thereof being hereby acknowledged, we ("ASSIGNOR") hereby sell or have sold, assign or have assigned, and otherwise transfer or have transferred to Vanda Pharmaceuticals Inc. (the "ASSIGNEE"), its successors, legal representatives, and assigns, my entire worldwide right, title, and interest in and to the Invention, the above-identified United States patent application, and any and all other patent applications and patents for the Invention which may be applied for or granted therefor in the United States and in all foreign countries and jurisdictions, including all divisions, continuations, reissues, reexaminations, renewals, extensions, counterparts, substitutes, and extensions thereof, and all rights of priority resulting from the filing of such applications and granting of such patents. In addition, we hereby authorize and request the Director of the United States Patent and Trademark Office to issue any United States Patent, and foreign patent authorities to issue any foreign patent, granted for the Invention, to ASSIGNEE, its successors, legal representatives, and assigns, my entire worldwide right, title, and interest in and to the same to be held and enjoyed by ASSIGNEE, its successors, legal representatives, and assigns to the full end of the terms for which any and all such patents may be granted, as fully and entirely as would have been held and enjoyed by us had this Assignment not been made; and we agree to execute any and all documents and instruments and perform all lawful acts reasonably related to recording this Assignment or perfecting title to the Invention and all related patents and applications, in ASSIGNEE, its successors, legal representatives, and assigns, whenever requested by ASSIGNEE, its successors, legal representatives, or assigns.

We acknowledge our prior and ongoing obligations to sell, assign, and transfer our rights under this Assignment to ASSIGNEE, and are unaware of any reason why we may not have the full and unencumbered right to sell, assign, and transfer our rights hereby sold, assigned, and transferred, and have not executed, and will not execute, any document or instrument in conflict herewith. We also hereby grant ASSIGNEE, its successors, legal representatives, and assigns, the right to insert in this Assignment any further identification (including, but not limited to, patent Application Number) which may be necessary or desirable for recordation of this Assignment. This Assignment is governed by the substantive laws of the State of New York, and any disputes will be resolved in a New York state court or federal court sited in New York.

DOCKET NUMBER: VAND-0182-US-PV

(1) Name of Inventor: Mihael H. Polymeropoulos

Signature: \_\_\_\_\_ Date: \_\_\_\_\_

(2) Name of Inventor: Sandra Smieszek

Signature: Sandra Smieszek Date: 9/5/2018